• Polarcool pivoted toward North America, prioritizing regulatory approvals for a 2026 launch of its PolarCap concussion treatment.
• Commercial buildout accelerated, with selection work under way for a U.S. distributor and a production partner.
• A 4 million MSEK bridge loan was raised in early Q3 to fund approval efforts, U.S. launch preparation, business development, and sales.
• Board proposed delisting from Spotlight Stock Market to free resources for North American market entry and scaling delivery capacity.
• Q2 operating revenue rose 13% to 0.8 MSEK, with Europe set for limited investment as focus shifts to North America.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polarcool AB published the original content used to generate this news brief via Cision (Ref. ID: 202608270900BITN____UKPR__SV_20260826-BIT-2722-0) on August 27, 2026, and is solely responsible for the information contained therein.